AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 202 min read$TEVA

Teva, Sanofi Report Sustained Duvakitug Benefits In Phase 2b IBD Study

Teva (TEVA) and Sanofi (SNY) reported positive Phase 2b data for duvakitug, showing sustained benefits in ulcerative colitis and Crohn's disease through Week 44. Clinical remission rates varied by dose, with higher rates observed at 900 mg. The drug was generally well tolerated. Both companies are advancing duvakitug into Phase 3 studies. SNY is up 4.11% at $41.19, while TEVA is down 0.41% at $41.14.

Original reporting
rttnews.com
Published Oct 20, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 4:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Teva, Sanofi Report Sustained Duvakitug Benefits In Phase 2b IBD Study — source image
Source · rttnews.com
Decision brief

The 30-second read

$TEVABullishMed
01

Why it matters

The data suggest duvakitug could become a first‑in‑class TL1A inhibitor, potentially expanding market share in IBD.

02

Market read

First disclosure of robust Phase 2b results for a novel IBD therapy, likely to influence biotech valuations.

03

What to watch

Regulatory timelines and competition from other IBD agents may temper price gains.

Relevance 9/10Novelty 9/10Timing: today

Background

Phase 2b data are a key milestone before pivotal Phase 3 trials, often moving biotech stocks.

Company-level read

Ticker impact

$TEVABullishHigh confidence
Context

Teva reported positive Phase 2b data for duvakitug in ulcerative colitis and Crohn's disease, showing high remission and response rates.

Expected impact

likely upside as investors price in potential Phase 3 success

Evidence & confidence

First disclosure of robust Phase 2b results for a novel TL1A antibody, a material catalyst for a listed biotech.

$SNYBullishHigh confidence
Context

Sanofi announced sustained improvements in ulcerative colitis and Crohn's disease from the same Phase 2b duvakitug study.

Expected impact

potential modest upside as market assesses partnership benefits

Evidence & confidence

First report of Sanofi's co‑development data, adding value to its pipeline.

Market effects

Sector

Strengthens the IBD therapeutic sector and may lift peer biotech valuations.

Regional

Positive for US biotech market; limited immediate regional effect.

Global

Adds to global pipeline confidence for TL1A‑targeted therapies.

Counterpoint

What could challenge this read

If later Phase 3 fails to meet endpoints, early optimism could reverse sharply.

Key entities

  • company
    Teva Pharmaceutical Industries Ltd.

    US‑listed biotech developing duvakitug.

  • company
    Sanofi

    Partner in duvakitug development.

Read at source← All news

StoryTeva and Sanofi report sustained 44‑week Phase 2b data for duvakitug in ulcerative colitis and Crohn’s disease

Also covered by

1 outlet

Related articles

OCT 20
$TEVAHigh

Teva Pharmaceutical Industries Ltd: UEG Week: Teva and Sanofi's Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn's Disease

Teva Pharmaceuticals and Sanofi reported positive 44-week data for duvakitug, their investigational treatment for ulcerative colitis (UC) and Crohn's disease (CD). The drug showed high rates of clinical remission, response, and endoscopic improvement in both conditions, with a favorable safety profile. Results were presented at UEG Week 2026, and phase 3 trials are ongoing.

finanznachrichten.de2 min
OCT 20
$TEVAMedAI 9/10

UEG Week: Teva and Sanofi's Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn's Disease

Teva Pharmaceuticals and Sanofi presented positive 44-week data from the RELIEVE UCCD phase 2b study, showing duvakitug maintained efficacy in ulcerative colitis (UC) and Crohn's disease (CD). The drug achieved high rates of clinical remission, response, and endoscopic improvement. Duvakitug was well-tolerated, with a safety profile consistent with the induction phase. The companies are advancing duvakitug in phase 3 trials for UC and CD, and a phase 2 study for hidradenitis suppurativa.

investingnews.com2 min
OCT 19
$SNYHigh

Japan Approves On-Body Injector for Subcutaneous Isatuximab in Multiple Myeloma

Japan approved the CirCLIQ Injector for subcutaneous isatuximab (Sarclisa) in multiple myeloma. The device, developed by Enable Injections and partnered with Sanofi, is the first on-body injector for anticancer treatment in Japan. Approval was based on the IRAKLIA trial showing noninferiority to IV administration. The injector delivers a fixed dose of 1400 mg without body weight adjustment. Similar approvals were previously granted in the US and EU.

onclive.com3 min